{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004046","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.734256+00:00","generated_at":"2026-06-20T17:50:27.949809+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viridian reports positive Phase 1/2 data for VRDN-001 in thyroid eye disease; 71% proptosis responders across doses","bullets":["3 mg/kg cohort: 67% proptosis responders, 56% overall responders, 67% achieved CAS 0/1, 20% complete diplopia resolution at week 6.","Across all 21 drug-treated patients: 71% proptosis responders, 67% overall responders, 62% CAS 0/1, 54% complete diplopia resolution.","No serious adverse events, discontinuations, or infusion reactions reported with VRDN-001 across dose levels.","Low-dose data support once-monthly subcutaneous dosing profile for VRDN-002 and VRDN-003; VRDN-003 IND planned Q2 2023.","Phase 3 THRIVE trial enrollment ongoing; results expected mid-2024; chronic TED proof-of-concept data expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004046","json":"https://secwatch.observer/filing/0001193125-23-004046.json","markdown":"https://secwatch.observer/filing/0001193125-23-004046.md","text":"https://secwatch.observer/filing/0001193125-23-004046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523004046/0001193125-23-004046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523004046/d427009d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:50:27.949809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}